Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Nathaniel D. Catron"'
Publikováno v:
ACS Omega, Vol 2, Iss 8, Pp 4207-4215 (2017)
Externí odkaz:
https://doaj.org/article/960defa278fd43f4a97effd6e19ee8c0
Autor:
Andrew J. Souers, Nathaniel D. Catron, Geoff G.Z. Zhang, Xilu Wang, Ahmed A. Suleiman, Deanne Stolarik, Yi Shi, Ahmad Y. Sheikh, Yeshwant D. Sanzgiri, Saul H. Rosenberg, Yu-Ming Pu, Darren C. Phillips, Chang H. Park, Rajeev M. Menon, Kennan C. Marsh, Richard A. Marks, Joel D. Leverson, Yi-Yin Ku, Russell C. Klix, John C. Kalvass, Russell A. Judge, Jianguo Ji, Gary J. Jenkins, Richard Hong, Kaid C. Harper, Keith M. Fournier, Steven W. Elmore, Rohinton Edalji, Shuang Chen, Jie Chen, Orlando F. Bueno, Zhi-Fu Tao, Ahmed Hamed Salem
Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other blood-related cancers. Reflecting the large and hydrophobic BH3-binding groove within BCL-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f852ee29a9488942fba6fce73ac0eaf
https://doi.org/10.1158/1535-7163.c.6543327.v1
https://doi.org/10.1158/1535-7163.c.6543327.v1
Autor:
Andrew J. Souers, Nathaniel D. Catron, Geoff G.Z. Zhang, Xilu Wang, Ahmed A. Suleiman, Deanne Stolarik, Yi Shi, Ahmad Y. Sheikh, Yeshwant D. Sanzgiri, Saul H. Rosenberg, Yu-Ming Pu, Darren C. Phillips, Chang H. Park, Rajeev M. Menon, Kennan C. Marsh, Richard A. Marks, Joel D. Leverson, Yi-Yin Ku, Russell C. Klix, John C. Kalvass, Russell A. Judge, Jianguo Ji, Gary J. Jenkins, Richard Hong, Kaid C. Harper, Keith M. Fournier, Steven W. Elmore, Rohinton Edalji, Shuang Chen, Jie Chen, Orlando F. Bueno, Zhi-Fu Tao, Ahmed Hamed Salem
1. Measured pKa values of ABBV-167 (Table S1. Ionization constants of ABBV-167) 2. Preparation of ABBV-167 on large scale (Scheme S1: Synopsis of GMP synthesis of ABBV-167) 3. Preparation of clinical ABBV-167 drug supply 4. Animal pharmacokinetics (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b82ad084c554229baf59a8bada6e495
https://doi.org/10.1158/1535-7163.22522290
https://doi.org/10.1158/1535-7163.22522290
Autor:
Paul Nimmer, Erwin R. Boghaert, Robin R. Frey, Phuong N Le, Andrew J. Souers, Peter Kovar, Wenqing Gao, Deepak Sampath, Dolores Diaz, Haichao Zhang, T. Matthew Hansen, Michael J. Mitten, Stephen K. Tahir, Russell A. Judge, Edna F. Choo, Yu Xiao, Shashank Shekhar, Xiaohong Song, George Doherty, Zhi-Fu Tao, Andrew S. Judd, Wayne J. Fairbrother, Michael D. Wendt, Steven W. Elmore, Kunzer Aaron R, Le Wang, Xilu Wang, Darren C. Phillips, Morey L. Smith, John A. Flygare, John Xue, Joel D. Leverson, Milan Bruncko, Chang H. Park, Nathaniel D. Catron
Publikováno v:
ACS Medicinal Chemistry Letters
Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-XL inhibitor that selectively and potently induces apoptosis in BCL-XL-dependent tumor cells. This molecule was generated by re-engineering our previously reported BCL-
Autor:
Darren C. Phillips, Gary J. Jenkins, Richard S. Hong, Chang H. Park, Richard A. Marks, Rohinton P. Edalji, Russell A. Judge, Geoff G. Z. Zhang, Nathaniel D. Catron, Jie Chen, Ahmed Salem, Ahmad Y. Sheikh, John C. Kalvass, Kaid C. Harper, Rajeev M. Menon, Kennan C. Marsh, Yeshwant D. Sanzgiri, Saul H. Rosenberg, Ahmed A. Suleiman, Yu-Ming Pu, Yi Shi, Keith M. Fournier, Zhi-Fu Tao, DeAnne Stolarik, Shuang Chen, Orlando F. Bueno, Xilu Wang, Jianguo Ji, Yi-Yin Ku, Andrew J. Souers, Joel D. Leverson, Russell C. Klix, Steven W. Elmore
Publikováno v:
Molecular cancer therapeutics. 20(6)
Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other blood-related cancers. Reflecting the large and hydrophobic BH3-binding groove within BCL-2
Autor:
Alan Donghua Zhu, Nathaniel D. Catron, Shaoxin Feng, John M. Lipari, Yi Gao, Geoff G. Z. Zhang, Jianwei Wu
Publikováno v:
Journal of Pharmaceutical Sciences. 107:2079-2090
Micellar solubilization is an important concept in the delivery of poorly water-soluble drugs. The rational selection of the type and the amount of surfactant to be incorporated in a formulation require comprehensive solubility studies. These studies
Autor:
Shweta A. Raina, David E. Alonzo, Yi Gao, Donghua Zhu, Lynne S. Taylor, Geoff G. Z. Zhang, Jianwei Wu, Nathaniel D. Catron
Publikováno v:
Pharmaceutical Research. 32:3350-3364
Many enabling formulations give rise to supersaturated solutions wherein the solute possesses higher thermodynamic activity gradients than the solute in a saturated solution. Since flux across a membrane is driven by solute activity rather than conce
Autor:
Russell A. Judge, Sha Jin, Lisa A. Hasvold, Andrew J. Souers, Guillaume Lessene, John Xue, Hans E. Purkey, Jun Chen, Chang H. Park, Sarah G. Hymowitz, Nathaniel D. Catron, Xilu Wang, Le Wang, Wayne J. Fairbrother, Brian J. Smith, Brad E. Sleebs, Erwin R. Boghaert, Kurt Deshayes, Chudi Ndubaku, Yu Xiao, Darren C. Phillips, Stephen K. Tahir, Steven W. Elmore, Michael J. Mitten, Zhi-Fu Tao, Keith G. Watson, Michael F. T. Koehler, Anatol Oleksijew, Saul H. Rosenberg, Peter Kovar, Paul Nimmer, Andrew M. Petros, Chris Tse, Morey L. Smith, Peter M. Colman, Haichao Zhang, Kerry Zobel, Joel D. Leverson, Peter E. Czabotar, John A. Flygare
Publikováno v:
ACS Medicinal Chemistry Letters. 5:1088-1093
A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Autor:
Jackie Lee, Darren C. Phillips, Sha Jin, Morey L. Smith, Yu Xiao, Heather Maecker, Nathaniel D. Catron, Saul H. Rosenberg, David C.S. Huang, Michael J. Mitten, John F. Seymour, Anatol Oleksijew, Stephen K. Tahir, Andrew J. Souers, Peter Kovar, Kylie D. Mason, Gerard M. Sullivan, Lloyd T. Lam, Chang H. Park, Sarah G. Hymowitz, Jun Chen, Scott L. Ackler, Steven W. Elmore, Rod A. Humerickhouse, Brian D. Dayton, Andrew W. Roberts, Cheol-Min Park, Sari H. Enschede, Haichao Zhang, Hong Ding, Wayne J. Fairbrother, John Xue, Kennan C. Marsh, Seong Lin Khaw, Deepak Sampath, Erwin R. Boghaert, Chris Tse, Paul Nimmer, Michael D. Wendt, Joel D. Leverson
Publikováno v:
Nature Medicine. 19:202-208
Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells
Publikováno v:
Biointerphases. 1:134-141
Poly(ethylene glycol) (PEG) is widely used in the pharmaceutical, biotechnology, and medical device industries. Although PEG is a biocompatible polymer that has enjoyed widespread use in drug delivery technology, it is not considered adhesive toward